Meeting
2019 ASCO Annual Meeting
Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.
Authors
Katya Losk
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Katya Losk , Rachel A. Freedman , Elizabeth A. Mittendorf , Zhenying Tan-Wasielewski , Lorenzo Trippa , Tari A. King
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 549)
DOI
10.1200/JCO.2019.37.15_suppl.549
Abstract #
549
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2021 ASCO Annual Meeting
MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.
First Author: Jose Antonio Lopez Guerrero
Poster
2018 ASCO Annual Meeting
Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.
First Author: William John Gradishar
Poster
2018 ASCO Annual Meeting
Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.
First Author: Philip Daniel Poorvu